News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Two new treatments funded for Parkinson’s disease

Media release

Two new treatments funded for Parkinson’s disease

Two new treatments will be subsidised from 1 November for people with Parkinson’s disease, government drug-funder PHARMAC announced today.

Ropinirole (Requip) and entacapone (Comtan) provide alternatives to treatments that are already funded, but which can cause serious side effects in some patients.

Ropinirole provides an alternative to drugs such as pergolide, which may increase the risk of heart valve problems for some patients, while entacapone can be used in place of tolcapone, which needs close monitoring of liver function by a specialist.

PHARMAC Chief Executive Wayne McNee says listing the two drugs is good news for people with Parkinson’s disease, and adds to the 12 treatments already funded.

“We’re pleased to be able to make more funded options available,” says Wayne McNee.

“The treatments that are already subsidised will continue to be effective and used by a considerable number of patients. But these decisions mean there will now be more funded options available, which is good news for patients and clinicians.”

Ropinirole is a dopamine agonist that acts to reduce the symptoms of Parkinson’s disease, including tremors (shaking) and slowness of movement. It can be taken on its own.

Entacapone is only used as a combination treatment. It acts to increase the duration that levodopa-based treatments are effective.

Wayne McNee says there are about 12,000 people taking subsidised anti-Parkinson’s agents, although only about 2000 of these are taking the comparable treatments to those being listed on 1 November.
PHARMAC estimates the new treatments will add $2.4 million to pharmaceutical spending over the next five years.

The decisions are the latest announced by PHARMAC as it continues its new investments programme. Recent decisions including widening access to salmeterol for asthma, alendronate for osteoporosis, mycophenolate for transplants, and the aromatase inhibitors for breast cancer.

ENDS

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 


Howard Davis: Controlling the High Ground

Stephen Johnson's raw and angry film not only poses important questions with scrupulous authenticity, but also provides a timely reminder of the genocidal consequences of casual bigotry and xenophobia. More>>

Howard Davis: Dryzabone - Robert Conolly's The Dry

After the terrible devastation caused by last year’s bushfires, which prompted hundreds of Australians to shelter in the ocean to escape incineration and destroyed uncountable amounts of wildlife, The Dry has been released during a totally different kind of dry spell. More>>


Howard Davis: Benjamin Ree's The Painter and The Thief

The Norwegian filmmaker had long been fascinated by art thieves who commit high-stakes crimes with a delicate touch when a chance Google search in 2015 uncovered a botched heist in Oslo. More>>


Howard Davis: Hit the Road, Jack - Chloé Zhao's Nomadland

Nomadland is perhaps the ultimately 'road' movie as it follows a group of dispossessed and disenfranchised vagabonds who find a form of communal refuge in camp sites and trailer parks after the economic contraction of 2008. More>>


Howard Davis: Byrneing Down the House - Spike Lee's American Utopia

Lee does an admirable job capturing Byrne's stunning live performance of his latest album, but the real star of the show is the staging. More>>


Howard Davis: The Phoenix Foundation Friend Ship Tour Docks in Wellington

A sense of local pride was certainly running high at the Opera House on Saturday night, as the lads ran through a tasty little set drawn mostly from their latest album Friend Ship (splash out for Xmas on the shocking pink extra-thick vinyl edition). More>>


 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland